CAC
SIOX

Cowen and Company’s Sio Gene Therapies Inc. Common Stock SIOX Stock Holding History

Cowen and Company’s Portfolio SIOX Stock Details SIOX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-22,500
Closed -$59K – 767
2021
Q1 		$59K Buy
22,500
+3,500
+18% +$9.9K ﹤0.01% 378
2020
Q4 		$53K Buy
+19,000
New +$55.3K ﹤0.01% 263

Other funds holding SIOX

SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
Hudson Bay Capital Management
Hudson Bay Capital Management Stamford, Connecticut $29B AUM 30.2% 1-Year Est. Return
TVWM
Tower View Wealth Management Shorewood, Wisconsin $227M AUM 41.04% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
GCP
GSA Capital Partners London, United Kingdom $1.61B AUM 28.28% 1-Year Est. Return

Cowen and Company's SIOX Position: Q2 2021 in Review

Cowen and Company sold out of Sio Gene Therapies Inc. Common Stock (SIOX) in Q2 2021, closing a stake of 22,500 shares — an estimated $59K sold.

Cowen and Company first reported a position in SIOX in Q4 2020 and held it in 2 quarters. The position peaked at $59K in Q1 2021. 54 funds tracked by Wall St. Rank hold SIOX as of Q2 2021.

  • Cowen and Company reported no remaining Sio Gene Therapies Inc. Common Stock position as of Q2 2021 after selling out during the quarter.
  • Cowen and Company sold 22,500 Sio Gene Therapies Inc. Common Stock shares in Q2 2021, an estimated $59K.
  • Cowen and Company first reported a position in Sio Gene Therapies Inc. Common Stock in Q4 2020 and held it in 2 quarters.
  • Cowen and Company's Sio Gene Therapies Inc. Common Stock position peaked at $59K in Q1 2021.
  • 54 funds tracked by Wall St. Rank held Sio Gene Therapies Inc. Common Stock as of Q2 2021.

Based on Cowen and Company's 13F filing for Q2 2021, filed 13 Aug 2021.